INS and type 2 diabetes mellitus: Similarly, a post-hoc analysis of SURPASS-1, enrolling 478 patients with T2D, found that all doses of tirzepatide as monotherapy increased insulin sensitivity compared to placebo, as suggested by the decreases in HOMA2-IR by 9–23% (vs +14.7% with placebo) and fasting insulin levels by 2–12% (vs +15%) and the increase in adiponectin by 16–23% (vs −0.2%) and IGFBP-2 by 38–70% (vs +4.1%) at 40 weeks [76].